NGIOinactive

NUGENEREX IMMUNO-ONCOLOGY, INC.

Healthcare·Oncology·Phase 2
OncologyInfectious Disease

NUGENEREX IMMUNO-ONCOLOGY, INC. (NGIO): 2 pipeline candidates · 1 clinical trial. Updated within the last hour.

6.9/10

BioSniper Score

3-factor signal · derived from public data

Cash RunwayN/A

N/A

Financial Health10.0

0% dilution

Pipeline Maturity6.0

Lead: Phase 2

Pipeline Breadth4.6

2 candidates

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for NUGENEREX IMMUNO-ONCOLOGY, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

—

Cash

—

Quarterly Burn

$1.7M

Runway

—

Revenue

—

Pipeline (2 candidates)

DrugPhase
ae37Phase 2
sars-cov-2 ii-key peptide vaccinePreclinical
1 clinical trial

Frequently asked questions

How many drug candidates are in NUGENEREX IMMUNO-ONCOLOGY, INC.'s pipeline?

NUGENEREX IMMUNO-ONCOLOGY, INC. (NGIO) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is NUGENEREX IMMUNO-ONCOLOGY, INC.'s lead drug candidate?

NUGENEREX IMMUNO-ONCOLOGY, INC.'s most advanced tracked candidate is ae37 (Phase 2) for Bladder cancer.

Get the full picture on NUGENEREX IMMUNO-ONCOLOGY, INC.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.

Start Free AnalysisBrowse Calendar